OR WAIT null SECS
Hosts are joined by Gary Scheiner, MS, of Integrated Diabetes Services, to discuss the latest developments in diabetes technology from the floor of the 83rd Scientific Sessions of the American Diabetes Association.
When it was launched in March 2022, Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives was created with the aim of bringing real-world perspective and breakdowns from leaders in diabetes management to a broader audience.
Created by a pair of certified diabetes care and education specialists in Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, each episode seeks to bridge the gap between the latest in research and what’s happening in clinical settings as well as the every day lives of people with diabetes.
While at the 83rd Scientific Sessions of the American Diabetes Association (ADA 2023), our hosts sat down with 10 expert guests to film 9 special edition episodes tackling subjects from foot care, obesity management, reducing insulin use, mental health, and more. One of these episodes included a sit-down with Gary Scheiner, MS, owner and clinical director of Integrated Diabetes Services.
Founded in 1995, Integrated Diabetes Services provides advanced education and mnaagement training to improve the quality of care for people with diabetes. In addition to this role with Integrated Diabetes Services, Scheiner is also the author of Think Like a Pancreas, which is billed as a practical guide to managing diabetes with insulin.
During the episode from ADA 2023, Scheiner discusses the latest news for insulin delivery systems, the importance of individualization in the management of diabetes, and his perspective on whether or not there is still need for DIY systems.
Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Relevant disclosures for Scheiner include Dexcom, Medtronic/Companion Medical, Eli Lilly, Xeris, and others.